A detailed history of Entry Point Capital, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 32,087 shares of ERAS stock, worth $69,949. This represents 0.06% of its overall portfolio holdings.

Number of Shares
32,087
Previous 80,546 60.16%
Holding current value
$69,949
Previous $172 Million 61.47%
% of portfolio
0.06%
Previous 0.16%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.67 - $2.55 $80,926 - $123,570
-48,459 Reduced 60.16%
32,087 $66.1 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $2.49 $134,511 - $200,559
80,546 New
80,546 $172 Million

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $266M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Entry Point Capital, LLC Portfolio

Follow Entry Point Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Entry Point Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Entry Point Capital, LLC with notifications on news.